Pure Global
NCT06405425

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 + PD-1 Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
BL-B01D1
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
May 01, 2026
Enrollment
52 participants
Primary outcome

Objective Response Rate (ORR)

Summary

This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1
 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06405425
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06405425 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sichuan Baili Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 52 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.